E-resources
PDF-
Ikari, Yuji; Matsue, Yuya; Torii, Sho; Hasegawa, Misaki; Aihara, Kazuki; Kuroda, Shunsuke; Sano, Takahide; Kitai, Takeshi; Yonetsu, Taishi; Kohsaka, Shun; Kishi, Takuya; Komuro, Issei; Hirata, Ken-ichi; Node, Koichi; Matsumoto, Shingo
Circulation Journal, 05/2021, Volume: 85, Issue: 6Journal Article
Background:Cardiovascular diseases and/or risk factors (CVDRF) have been reported as risk factors for severe coronavirus disease 2019 (COVID-19).Methods and Results:In total, we selected 693 patients with CVDRF from the CLAVIS-COVID database of 1,518 cases in Japan. The mean age was 68 years (35% females). Statin use was reported by 31% patients at admission. Statin users exhibited lower incidence of extracorporeal membrane oxygenation (ECMO) insertion (1.4% vs. 4.6%, odds ratio OR: 0.295, P=0.037) and septic shock (1.4% vs. 6.5%, OR: 0.205, P=0.004) despite having more comorbidities such as diabetes mellitus.Conclusions:This study suggests the potential benefits of statins use against COVID-19.
